(Q42546011)

2 November 2017

title

Sho-saiko-to, a traditional Kampo medicine, enhances the anti-HIV-1 activity of lamivudine (3TC) in vitro (English)

1 reference

2 November 2017

1 reference

Piras G

1 reference

2 November 2017

Makino M

series ordinal

1 reference

2 November 2017

Baba M

series ordinal

1 reference

2 November 2017

language of work or name

1 reference

1 January 1997

1 reference

Microbiology and Immunology

2 November 2017

published in

1 reference

2 November 2017

1 reference

2 November 2017

1 reference

2 November 2017

page(s)

835-839

1 reference

Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro

2 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

Inhibition of HIV replication in lymphocyte cultures of virus-positive subjects in the presence of sho-saiko-to, an oriental plant extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

Inhibition of reverse transcriptase activity by a flavonoid compound, 5,6,7-trihydroxyflavone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

Differential inhibition of the activities of reverse transcriptase and various cellular DNA polymerases by a traditional Kampo drug, Sho-saiko-to

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1348-0421.1997.TB01937.X

10.1111/J.1348-0421.1997.TB01937.X

21 January 2018

Identifiers

DOI

1 reference

2 November 2017

1 reference